EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Performance of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity Thresholds

Kristin Ranheim Randel, Edoardo Botteri, Thomas de Lange iD, Anna Lisa Schult iD, Sigrun Losada Eskeland, Badboni El-Safadi, Espen R Norvard, Nils Bolstad, Michael Bretthauer, Geir Hoff, Øyvind Holme

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18314 ↗

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Kristin Ranheim Randel and 10 co-authors. Institution: Department of Research and Development, Telemark Hospital, Skien, Norway. Major MEDLINE topics: Colonoscopy, Colorectal Neoplasms, Early Detection of Cancer, Feces. Cited 6 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Helse Sør-Øst RHF, Norwegian Parliament.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The positivity thresholds of faecal immunochemical testing (FIT) in colorectal cancer (CRC) screening vary between countries.

Aims

To explore the trade‐off between colonoscopies performed, adverse events and lesions detected at different FIT thresholds in a Norwegian CRC screening trial.

Methods

We included first participation in biennial FIT screening for 47,265 individuals aged 50–74 years. Individuals with FIT > 15 μg Hb/g faeces were referred for colonoscopy. We estimated the number of colonoscopies, adverse events, screen‐detected CRCs, advanced adenomas and serrated lesions expected at FIT thresholds currently or recently used in other European countries ranging between 20 and 150 μg/g.

Results

At the 15 μg/g threshold (Norway), 3705 participants underwent colonoscopy, of whom 203 had CRC, 1119 advanced adenomas and 256 advanced serrated lesions. Using a 47 μg/g threshold, 1826 (49.3%) individuals would have undergone colonoscopy, and 154 (75.9%) would have been diagnosed with CRC, 702 (62.7%) with advanced adenoma and 128 (50.0%) with advanced serrated lesion compared to the 15 μg/g threshold. At 150 μg/g, the corresponding figures would have been 838 (22.6%) undergoing colonoscopy, 114 (56.2%) with CRC, 345 (30.8%) advanced adenoma and 54 (21.1%) advanced serrated lesions. The detection rate of stage I CRC was 0.22% at 15 μg/g and 0.11% at 150 μg/g. Post‐colonoscopy bleeding rates were 0.8% and 1.7%, respectively.

Conclusions

Increasing the FIT threshold reduces colonoscopy demand, but substantially decreases lesion detection and unfavourably changes CRC stage distribution. The risk of adverse events at colonoscopy increased with FIT threshold, requiring country‐specific information on adverse events. Trial Registration Clinicaltrials.gov identifier: NCT01538550

Subjects

MeSH terms (MEDLINE)

ColonoscopyColorectal NeoplasmsEarly Detection of CancerFecesOccult BloodAgedFemaleHumansMaleMiddle AgedAdenomaImmunochemistryMass ScreeningNorway

Author keywords

adverse eventcolorectal cancer screeningcolorectal neoplasiacut‐off levelimmunochemical faecal occult blood test

Authors and institutions

  • Department of Research and Development, Telemark Hospital, Skien, Norway.
  • Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Section for Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
  • Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
  • Department of Medicine, Sahlgrenska University Hospital-Mölndal, Region Västra Götaland, Sweden.
  • Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

ORCID profiles: Thomas de Lange, Anna Lisa Schult

Funding

  • Helse Sør-Øst RHF
  • Norwegian Parliament

Cite

APA

Randel, K. R., Botteri, E., de Lange, T., Schult, A. L., Eskeland, S. L., El-Safadi, B., Norvard, E. R., Bolstad, N., Bretthauer, M., Hoff, G., & Holme, Ø. (2025). Performance of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity Thresholds. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18314

Vancouver

Randel KR, Botteri E, de Lange T, Schult AL, Eskeland SL, El-Safadi B, et al. Performance of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity Thresholds. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18314

BibTeX
@article{Randel2025,
  author = {Randel, Kristin Ranheim and Botteri, Edoardo and de Lange, Thomas and Schult, Anna Lisa and Eskeland, Sigrun Losada and El-Safadi, Badboni and Norvard, Espen R and Bolstad, Nils and Bretthauer, Michael and Hoff, Geir and Holme, Øyvind},
  title = {Performance of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity Thresholds},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18314}
}
Start for free →